… life sciences companies including Regeneron, Amgen, Gilead Sciences, Daiichi Sankyo, that … may cause actual performance and financial results in future periods to differ …

… clinical-stage programs, today announced financial results for the first quarter ended … the transaction. FIRST QUARTER 2025 FINANCIAL RESULTS Cash Position: As of March … of costs incurred under the Amgen Collaboration Agreement. G&A …

… today announced first quarter 2025 financial results and provided a business update … Squibb, Amgen, Astellas, Regeneron, and Moderna. First Quarter 2025 Financial Results: Cash … multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, …

… Incorporated (Nasdaq: LGND) today reported financial results for the three months ended … proven strategy.” First Quarter 2025 Financial Results Total revenues and other income … ’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead …

… investments. First Quarter 2025 Financial Results Product revenue, net was … FGFR2b) Zai Lab partner Amgen to provide data readout … China. Zai Lab partner Amgen to provide data readout … our business operations and financial results and provide investors with …

… BeOne Medicines, Ltd., today announced financial results and corporate updates from the … period. In-licensed products from Amgen and TEVIMBRA also contributed to … lung cancer in collaboration with Amgen. Anti-TIGIT antibody: Discontinued clinical …

… oncology company, today announced financial results for the first quarter … began his career at Amgen as a Research Associate … including Finance Director of Amgen Worldwide and Head of … Genelux. First Quarter 2025 Financial Results Cash, cash equivalents and …

… patients with cancer, today reported financial results for the three months ended … the year. First Quarter 2025 Financial Results Revenue: Revenue for the first … Company’s collaboration agreement with Amgen. R&D Expenses: Research …

… it will report first quarter financial results on Monday, May 12, 2025 … multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron …

"Amgen has been a leading U.S.-based manufacturer of biologic medicines since 1988. Today's investment reinforces our ongoing commitment to expanding U.S. manufacturing and ensuring patients around the world have access to our innovative medicines …